On Demand

IBRANCE® (palbociclib) Oligometastases

Dr. John Connibear

In this video Dr. Connibear provides his professional opinion on the following topics:

  • Definition of oligometastatic disease
  • What challenges do oligometastases present in breast cancer?
  • How do you decide treatment for patients with metastatic breast cancer?
  • How might we drive better outcomes in oligometastatic breast cancer?
On Demand

IBRANCE® (palbociclib) locally advanced breast cancer

Dr. Henry Cain

In this video Henry Cain provides his professional opinion on the following topics:

  • What is locally advanced inoperable breast cancer?
  • What is the significance of the MDT, and of the patient’s opinion and quality of life when deciding therapy?
  • What could CDK4/6 inhibitors, such as Ibrance mean for patients with ER+, HER2- locally advanced disease?
On Demand

The IMPACT webinar series - guidance for Cardiovascular Physicians

Dr Sandy Gupta

Bernadette Downey

1. Dr Sandy Gupta and Bernadette Downey discuss the ‘deadly duo’ of smoking and cardiovascular disease and the health benefits of smoking cessation. They also highlight their experiences of the changing environment of smoking cessation services and re-enforce the need for a whole system approach across primary and secondary care.

On Demand

The IMPACT webinar series - guidance for General Practitioners and Nurses

Dr Stephen Gaduzo

Nurse Lisa Fendell

1. GP Stephen Gaduzo and Smoking Cessation Advisor Lisa Fendall discuss how smoking is a significant cause of long term diseases such as COPD, cardiovascular disease and diabetes and the substantial health benefits of quitting smoking for these patient groups.

On Demand

IBRANCE® (palbociclib) visceral disease

Peter Schmid | Professor of Cancer Medicine at Barts Cancer Institute

In the visceral disease video Prof Peter Schmid provides his professional opinion on the following topics:

  • Definition of visceral metastasis in breast cancer
  • What factors do you consider when a patient presents with visceral disease
  • How CDK4/6 inhibitors have changed the management of visceral disease.
  • What have CDK4/6 inhibitors meant for quality of life in this patient group
  • When would you prescribe Ibrance and endocrine therapy for your patient with visceral disease
On Demand

IBRANCE® (palbociclib) interactive case study

Chris Poole | Consultant Medical Oncologist, University Hospital Coventry And Warwickshire

In this video Prof Chris Poole provides his professional opinion on the following topics:

  • Case of a patient with visceral metastasis
On Demand

The IMPACT webinar series - guidance for Respiratory Physicians

Keir Lewis - Swansea University

1. Professor Keir Lewis discusses the burden of smoking and the impact that the subsequent chronic respiratory conditions in patients has on the NHS.

On Demand

XALKORI in ALK+ advanced NSCLC: Efficacy in a real world setting

Dr Shobhit Baijal

Dr Shobit Baijal explores the use of real world data to understand, in further detail, the use of Xalkori® in patients with ALK+ advanced NSCLC. He illustrates this by talking through a number of real world, retrospective, cohort study data that provides findings in support of sequential therapy with Xalkori®.

On Demand

Accurate and efficient detection of the ALK gene rearrangement in NSCLC

Professor John Gosney

After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ALK gene and the gold-standard method to detect the ALK gene rearrangement.

On Demand

The use of XALKORI® within ROS1+ advanced NSCLC

Dr Rohit Lal

Dr Rohit Lal explains the use of Xalkori in ROS1+ advanced NSCLC through PROFILE 10011 study data before presenting real world data provided through a ROS1 clinical case study.